IP Library › Granted Patent US 12,221,480
Granted Patent B2
US 12,221,480 · App. 16/764,796 · Granted Feb 11, 2025

Methods for selective expansion of delta-3 gamma delta T-cell populations and compositions thereof

Inventors: Aya Jakobovits (Beverly Hills, CA); Daulet Kadyl Satpayev (Redwood City, CA); Orit Foord (Foster City, CA); Yifeng Frank Jing (Hayward, CA); Hui Shao (Foster City, CA); Jason Michael Romero (East Palo Alto, CA); Mary Michael Brody (Menlo Park, CA); Matthew Ian Hoopes (Menlo Park, CA)
C07K16/2809A61K39/4611A61K39/4631A61K39/464424C12N5/0636C07K2317/92C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,221,480
App. No.
16/764,796
Granted
Feb 11, 2025
Kind
B2
Abstract

The present application is directed to agents that bind an epitope specific to a δ3 γδ TCR. Such agents can be, but are not limited to, an antibody or fragment thereof. Also described herein are methods for using the agents, e.g., to expand or selectively expand δ3 γδ T cells. Also described herein are methods of using expanded δ3 γδ T cells for treatment of a subject in need thereof.

Claims (91)

1. An antibody or fragment thereof that binds an epitope specific to a δ 3 γδ TCR, wherein the antibody or fragment thereof comprises:

(i) a heavy chain variable region/light chain variable region (HCVR/LCVR) sequence pair selected from the group consisting of SEQ ID NOs: 1/8, 2/9, 3/10, 4/11, 5/12, 6/13, and 7/14; or a HCVR/LCVR pair comprising

(ii) the six complementarity determining regions (CDRs) of a HCVR/LCVR sequence pair selected from the group consisting of SEQ ID NOs: 1/8, 2/9, 3/10, 4/11, 5/12, 6/13, and 7/14.

2. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises:

a) the six CDRs of a HCVR/LCVR sequence pair selected from the group consisting of SEQ ID NOs: 1/8, 3/10, 4/11, 5/12, 6/13, and 7/14;

b) the six CDRs of a HCVR/LCVR sequence pair selected from the group consisting of SEQ ID NOs: 1/8, 3/10, 5/12, and 7/14;

c) the six CDRs of a HCVR/LCVR sequence pair selected from the group consisting of SEQ ID NOs: 3/10, 5/12, and 7/14;

d) the six CDRs of a HCVR/LCVR sequence pair selected from the group consisting of SEQ ID NOs: 4/11 and 5/12;

e) the six CDRs of a HCVR/LCVR sequence pair consisting of SEQ ID NOs: 1/8; or

f) the six CDRs of a HCVR/LCVR sequence pair consisting of SEQ ID NOs: 4/11.

3. The antibody or fragment thereof of claim 1 , wherein the antibody binds to:

i) a region distal from the γ-chain binding interface of Vδ3;

ii) β strand D and E of the Vδ3 of the γδ TCR according to IMGT nomenclature;

iii) β strand C″ and D and a loop between β strands E and F of the Vδ3 of the γδ TCR according to IMGT nomenclature; or

iv) β strand A, B, D, and E of the Vδ3 of the γδ TCR according to IMGT nomenclature.

4. The antibody or fragment thereof of claim 2 or claim 3 , wherein:

(i) the antibody or fragment thereof selectively expands a δ3 γδ T cell as compared to αβ T cells in a mixed cell population comprising γδ T cells and αβ T cells;

(ii) the antibody or fragment thereof is bound to a δ3 γδ TCR, optionally wherein the δ3 γδ TCR is expressed on the surface of a δ3 γδ T cell; or

(iii) the antibody or fragment thereof is bound to an extracellular surface of an antigen presenting cell (APC), optionally wherein the antibody or fragment thereof is anchored in the membrane of the APC or wherein an Fc region of the antibody or fragment thereof is bound to an Fc-receptor expressed by the APC.

5. A nucleic acid encoding any one of the antibodies or fragments thereof according to claim 1 , wherein the nucleic acid is operably linked to a heterologous promoter.

6. A host cell comprising any one of the antibodies or fragments thereof according to claim 1 , or a nucleic acid according to claim 5 ; optionally wherein the host cell is an artificial antigen presenting cell (aAPC).

7. A method of making an antibody or fragment thereof that binds an epitope specific to a δ3 γδ TCR, the method comprising culturing the host cell of claim 6 under conditions sufficient to produce the antibody or fragment thereof.

8. An ex vivo method for producing an enriched γδ T cell population, comprising contacting a first cell population comprising γδ T cells with one or more antibodies or fragments thereof according to claim 1 .

9. The method of claim 8 , wherein:

(i) the first cell population is an isolated mixed cell population comprising αβ T cells and γδ T cells, optionally wherein the first cell population comprises, or is, a sample of peripheral blood mononuclear cells (PBMCs) or wherein the first cell population is selected from a peripheral blood sample, a leukapheresis sample, a cord blood sample, a tumor sample, or a tissue sample;

(ii) the first cell population comprises less than 1% δ3 γδ T cells;

(iv) the first cell population comprises uncultured primary cells or unpassaged primary cells;

and/or

(v) the method comprises directly contacting the isolated mixed cell population with the one or more antibodies or fragments thereof.

10. The method of claim 8 , wherein:

(i) the first cell population comprises one or more engineered γδ T cells; and/or

(ii) the first cell population comprises expanded γδ T cells, optionally wherein the method comprises a first γδ T cell expansion and a second γδ T cell expansion.

11. The method of claim 8 , wherein:

(i) the method comprises producing an enriched γδ T cell population comprising at least 10 8 δ3 γδ T cells, optionally wherein the enriched γδ cell population comprising at least 10 8 δ3 γδ T cells is produced within 12 to 21 days; and/or

(ii) wherein the method comprises expanding the δ3 γδ T cells in the first cell population at least 1,000-fold, optionally wherein the specified-fold expansion is achieved within 12 to 21 days.

12. An ex vivo method for producing an enriched γδ T cell population, comprising:

a) contacting a first cell population comprising γδ T cells with one or more first activating agents that activate and expand γδ T cells, thereby producing an expanded first γδ T cell population; and

b) contacting the expanded first γδ T cell population with one or more second activating agents that activate and expand γδ T cells, thereby producing the enriched γδ T cell population,

wherein at least one of the one or more first activating agents or at least one of the one or more second activating agents is an antibody or fragment thereof according to claim 1 .

13. The method of claim 12 , wherein:

(i) the method comprises isolating the expanded first γδ T cell population after a) and before b);

(ii) a) comprises culturing the first cell population in the presence of an antigen presenting cell (APC) and the one or more first activating agents or b) comprises culturing the expanded first γδ T cell population in the presence of an antigen presenting cell (APC) and the one or more second activating agents;

(iii) the first cell population is:

(I) an isolated mixed cell population comprising αβ T cells and γδ T cells, optionally wherein the first cell population is selected from a peripheral blood sample, a leukapheresis sample, a cord blood sample, a tumor sample, or a tissue sample or wherein the first cell population comprises, or is, a sample of peripheral blood mononuclear cells (PBMCs); optionally wherein the first cell population comprises uncultured primary cells, unpassaged primary cells; or

(II) a population of engineered γδ T cells;

(iv) the method comprises genetically engineering the expanded first γδ T cell population or genetically engineering the enriched γδ T cell population;

(v) the method comprises producing an enriched γδ T cell population comprising at least 10 8 δ3 γδ T cells, optionally wherein the enriched γδ T cell population comprising at least 10 8 δ3 γδ T cells is produced within 12 to 21 days;

(vi) the method comprises expanding the δ3 γδ T cells in the first cell population at least 1,000-fold, optionally wherein the specified-fold expansion is achieved within 12 to 21 days;

(vii) at least one of the one or more first activating agents is structurally identical to at least one of the one or more second activating agents;

(viii) at least one of the one or more first activating agents is structurally different than at least one of the one or more second activating agents; and/or

(ix) at least one of the one or more first activating agents or at least one of the one or more second activating agents is immobilized, optionally wherein the immobilized activating agent is immobilized on a surface of a culture vessel or on a surface of an antigen presenting cell (APC) or an artificial antigen presenting cell (aAPC); optionally wherein immobilized activating agent is the antibody or fragment thereof that binds the epitope specific to a δ3 γδ TCR.

14. A method according to claim 8 , wherein the method achieves greater than 30% δ3 γδ T cells prior to, or in the absence of, αβ T cell depletion, preferably greater than 40%.

15. An enriched γδ T cell population, which is produced by a method according to claim 8 or 12 , wherein greater than 30% of the γδ T cells are δ3 γδ T cells, preferably greater than 40%, more preferably greater than 60%, yet more preferably greater than 70%, even more preferably greater than 80% before positive or negative selection for δ3 γδ T cells; optionally wherein:

(i) the γδ T cell population comprises polyclonal TCR diversity, optionally wherein greater than 60% or 70% the δ3 T-cells express the phenotype CD45RA+/CD27+ and/or CD45RA-/CD27+;

(ii) the γδ T cell population is derived from tumor infiltrating lymphocytes;

(iii) the γδ T-cells express an endogenous or heterologous tumor recognition moiety;

(iv) the population comprises a therapeutically effective amount of γδ T-cells;

(v) the γδ T cell population comprises anti-tumor cytotoxicity that is independent of NKp30 activity, NKp44 activity, and/or NKp46 activity, optionally wherein the γδ T cell population does not comprise NKp30 activity-dependent anti-tumor cytotoxicity, NKp44 activity-dependent anti-tumor cytotoxicity, and/or NKp46 activity-dependent anti-tumor cytotoxicity; and/or

(vi) wherein less than 40% of the γδ T cells express a detectable level of NKp30, NKp44, and/or NKp46.

16. An enriched γδ T cell population, which is produced by a method according to claim 8 or 12 , wherein the enriched γδ T cell population comprises from 20% to 50% δ3 γδ T cells before positive or negative selection for δ3 γδ T cells.

17. A method of treating cancer, an inflammatory disease, or an autoimmune disease in a subject in need thereof, the method comprising:

a) providing a therapeutically effective amount of an enriched γδ T cell population according to claim 15 or claim 16 ; and

b) administering the therapeutically effective amount of the enriched γδ T cell population to the subject.

18. The method according to claim 17 , wherein the method further comprises admixing the enriched γδ T cell population with a second expanded γδ T cell population to form an admixed population and administering the admixed population to the subject; optionally wherein:

(i) the second expanded γδ T cell population comprises>60% δ1 or>60% δ2 γδ T cells;

(ii) the admixed γδ T cell population comprises>60% δ1 or>60% δ2 γδ T cells; or

(iii) the admixed γδ T cell population comprises>60% δ3 γδ T cells.

19. The method of claim 8 or 12 , further comprising genetically engineering the γδ T cells.

20. The method of claim 19 , wherein the method comprises genetically engineering the enriched γδ T cell population.

21. The method of claim 19 , wherein the γδ T cells are engineered to express one or more tumor recognition moieties.

22. The method according to 20 or 21 , wherein:

a) the engineered γδ T cells lack an HLA locus;

b) the engineered γδ T cells are universal donor cells;

c) the engineered γδ T cells are tumor-specific allogeneic γδ T cells; or

d) the γδ T cells are engineered to express two or more tumor recognition moieties.

23. The method according to claim 22 (d):

i) wherein the two or more tumor recognition moieties are different, wherein each different tumor recognition moiety is engineered to recognize different epitopes of the same antigen; or

ii) wherein the two or more tumor recognition moieties are different, wherein each different tumor recognition moiety is engineered to recognize different epitopes of different antigens.

24. The method according to claim 21 , wherein:

a) the tumor recognition moiety is derived from a tumor infiltrating lymphocyte;

b) the tumor recognition moiety is cloned from a T-cell;

c) the tumor recognition moiety is an engineered T-cell receptor;

d) the tumor recognition moiety is an antibody, an antibody fragment, a scFv, a single domain antibody, or a Fab, that recognizes a tumor antigen; or

e) the tumor antigen is a peptide-MHC complex, and the tumor recognition moiety recognizes the peptide-MHC complex.

25. The method according to claim 24 (c), wherein:

i) the engineered T-cell receptor is derived from a human or a mouse T-cell receptor;

ii) the engineered T-cell receptor is an engineered αβ TCR; or

iii) the engineered T-cell receptor is an engineered γδ TCR.

26. The method according to claim 20 or 21 , wherein the γδ T cells are engineered to express an antigen recognition moiety, wherein the antigen recognition moiety recognizes an antigen associated with an autoimmune disease, or wherein the antigen recognition moiety recognizes a pathogenic antigen, wherein the pathogenic antigen is derived from a pathogenic bacterium or a virus.

27. The method of claim 8 or 12 , further comprising depleting αβ T cells, B cells and/or NK cells in the enriched γδ T-cell population.

28. A composition comprising the enriched γδ T cell population of claim 16 ; and the at least one antibody or fragment thereof of claim 1 .

Assignments (1)
CHANGE OF NAME Recorded Dec 6, 2022
From: ADICET BIO, INC.
To: ADICET THERAPEUTICS, INC.
Reel/Frame 062002/0241 →
Continuity (2)
Provisional Application 62586782 · Nov 15, 2017
Related Publication 20230257462A1 · Aug 17, 2023
References Cited (128)
US 5185250A · Brenner et al. · 1993 [cited by applicant]
US 5260223A · Brenner et al. · 1993 [cited by applicant]
US 7728114B2 · Mach et al. · 2010 [cited by applicant]
US 7985739B2 · Kay et al. · 2011 [cited by applicant]
US 9540448B2 · Scheinberg et al. · 2017 [cited by applicant]
US 20030138433A1 · Newell et al. · 2003 [cited by applicant]
US 20060026986A1 · Wang et al. · 2006 [cited by applicant]
US 20060122130A1 · Rabbani · 2006 [cited by applicant]
US 20060205089A1 · Dratz et al. · 2006 [cited by applicant]
US 20080026986A1 · Wang et al. · 2008 [cited by applicant]
US 20080171014A1 · Wu et al. · 2008 [cited by applicant]
US 20100272739A1 · Gelfand et al. · 2010 [cited by applicant]
US 20120034221A1 · Bonvini et al. · 2012 [cited by applicant]
US 20140141513A1 · De Carvalho Silva Santos et al. · 2014 [cited by applicant]
US 20150259645A1 · Poupot et al. · 2015 [cited by applicant]
US 20180169147A1 · Anjos et al. · 2018 [cited by applicant]
CN 1506456A · 2004 [cited by applicant]
CN 102994448A · 2013 [cited by applicant]
WO WO1993020221A1 · 1993 [cited by applicant]
WO WO2001022816A1 · 2001 [cited by applicant]
WO WO2003087341A2 · 2003 [cited by applicant]
WO WO2011090804A1 · 2011 [cited by applicant]
WO WO2012012667A2 · 2012 [cited by applicant]
WO WO2012156958A2 · 2012 [cited by applicant]
WO WO2013074916A1 · 2013 [cited by applicant]
WO WO2013079174A1 · 2013 [cited by applicant]
WO WO2014009370A2 · 2014 [cited by applicant]
WO WO2014134412A1 · 2014 [cited by applicant]
WO WO2015061694A2 · 2015 [cited by applicant]
WO WO2015156673A2 · 2015 [cited by applicant]
WO WO2016081518A2 · 2016 [cited by applicant]
WO WO2016198480A1 · 2016 [cited by applicant]
WO WO2017011804A1 · 2017 [cited by applicant]
WO WO2017197347A1 · 2017 [cited by applicant]
Romagné et al. (Journal of Immunological Methods. 189(1):25-36 (1996)) (Year: 1996). [cited by examiner]
Zhao et al. J Transl Med16(3):1-13. (2018) (Year: 2018). [cited by examiner]
Zhou et al. Cell Mol. Immunol. 9:34-44 (2012) (Year: 2012). [cited by examiner]
Almagro & Fransson, Frontiers in Bioscience 2008; 13:1619-33 (Year: 2018). [cited by examiner]
Chiu et al., Antibodies, 8(55):1-80. (2019) (Year: 2019). [cited by examiner]
Lobner et al., Immunol Rev 270:113-131 (2016) (Year: 2016). [cited by examiner]
Ali et al., “γδ T Cell Immune Manipulatino during Chroinic Phase of Simian HIV Infection Confers Immunological Benefits”, J. Immunol., vol. 183, No. 8, pp. 5407-5417 (2009). [cited by applicant]
Appay et al, “Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections,” Nature Medicine, vol. 8, pp. 379-385 (2002). [cited by applicant]
Bauer et al, Gene Therapey for HIV: From Inception 49 to a Possible Cure, SpringBriefs in Biochemistry and Molecular Biology, Chapter 7, pp. 49-54 (2014). [cited by applicant]
Biocompare, “Monoclonal Antibody Anti-Human TCR PAN [gamma]/[delta] PN IM1349—Purified—Freeze-dried—0.1 mg—Clone IMMU510 for Research Use Only. Not for use in diagnostic procedures”, Beckman Coulter: Jan. 1, 2006, p. 1,… [cited by applicant]
Bornstein et al, “Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies,” Investigational New Drugs., Vo. 28, Issue 5, pp. 561-574 (2010). [cited by applicant]
Boucherma et al., “HLA-A 01:03, HLA-A 24-02, HLA-B8:08-01, HLA-B 27:05, HLA-B 35:01, HLA-B 44:02, and HLA-C 07:01 Monochain Transgenic/H-2 Class | Null Mice: Novel Versatile Preclinical Models of Human T Cell Responses,… [cited by applicant]
Carding and Egan, “γδ TCells: Functional Plasticity and Heterogeneity,” Nat Rev Immunol vol. 2, pp. 336-345 (2002). [cited by applicant]
Cheever et al., “The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research,”Clin. Cancer Res., vol. 15(17), pp. 5323-5337 (2009). [cited by applicant]
Chen et al., “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen,” J. Mol. Biol. vol. 293, pp. 865-881 (1999). [cited by applicant]
Chothia and Lesk, “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol., vol. 196, pp. 901-917 (1987). [cited by applicant]
Chothia et al., “Conformations of immunoglobulin hypervariable regions,”Nature, vol. 342, pp. 878-883 (1989). [cited by applicant]
Ciccone, “A monoclonal antibody specific for a common determinant of the human T cell receptor gamma/delta directly activates CD3+WT31—lymphocytes to express their functional program(s)”, The Journal of Experimental Med… [cited by applicant]
Dao et al. “Targeting the intracellular WT1 oncogene product with a therapeutic human antibody” Science translational medicine, vol. 5(176): 176ra33, pp. 1-22 (2013). [cited by applicant]
Damschroder et al., “Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies,” Mol Immunol, vol. 41(10) pp. 985-1000 (2004). [cited by applicant]
Daubenberger et al., “Functional and Structural Similarity of Vγ9V δ2 T Cells in Humans and Aotus Monkeys, a Primate Infection Model for [cited by applicant]
Davis and Merwe, “The structure and ligand interactions of CD2: implications for T-cell function,” Immunol. Today, vol. 17, Issue 4, pp. 177-187 (1996). [cited by applicant]
Deniger et al., “Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous γδ T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor,” Molecular Therapy, vol. 21, No. 3, pp. 638-647 (2013). [cited by applicant]
Dohan & Reiter, “T-cell-receptor-like antibodies—generation, function and applications,”Expert Rev Mol Med., vol. 14(e6), pp. 1-17 (2012). [cited by applicant]
Dokouhaki et al, Adoptive immunotherapy of cancer using ex vivo expanded human γδ T cells: A new approach, Cancer Letters, vol. 297, pp. 126-136 (2010). [cited by applicant]
Edwards et al, “The Remarkable Flexibility of theHuman Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS”, J. Mol. Biol., vol. 334, pp. 102-118 (2003). [cited by applicant]
Ehl et al., “A variant of SCID with specific immune responses and predominance of gamma delta T cells”, J. of Clinical Investigation, vol. 115, No. 11, pp. 3140-3148 (2005). [cited by applicant]
Fisher et al., “Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells,” Clinical Cancer Research, vol. 20, No. 22, pp. 5720-5732 (2014). [cited by applicant]
Gonzalez et al., “Humanized mice: novel model for studying mechanisms of human immune-based therapies,” Immunol. Res. vol. 57, pp. 326-334 (2013). [cited by applicant]
Gra et al., “Analysis of T-Cell Receptor-γ Gene Rearrangements Using Oligonucleotide Microchip: A Novel Approach for the Determination of T-Cell Clonality,” Journal of Molecular Diagnostics, vol. 9, No. 2 pp. 249-257 (2… [cited by applicant]
Green, et al., “Recognition of nonpeptide antigens by human V gamma 9V delta 2 T cells requires contact with cells of human origin”, Clin Exp Immunol., vol. 136(3), pp. 472-482 (2004). [cited by applicant]
Groh et al., “Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB,” PNAS, vol. 96, pp. 6879-6884 (1999). [cited by applicant]
Hamers-Casterman et al., “Naturally occurring antibodies devoid of light chains,” Nature, vol. 63, pp. 446-448 (1993). [cited by applicant]
Harlow et al. Antibodies, A Laboratory Manual, Cold Spring Harbor laboratory, pp. 37-47 (1988). [cited by applicant]
Hayday A.C., “γδ Cells: A Right Time and Right Place for a Conserved Third Way of Protection,” Annu Rev Immunol. vol. 18, pp. 975-1026 (2000). [cited by applicant]
Hayday and Pennington, “Key factors in the organized chaos of early T cell development,” Nature Immunology. vol. 8, No. pp. 137-144 (2007). [cited by applicant]
Hiasa et al., “Dual specificity of αβ-γδ TCR T cells: transformation of Vγ9Vδ2 T cells with MAGE-A4143-151 specific αβ type TCR genes,” Annual Meeting of the Japanese Cancer Association, vol. 66, p. 423 (2007). [cited by applicant]
Hua et al., “Potentinal regulatory role of in vitro-expanded Vδ1 T cells from human peripheral blood,” Immunol Res. vol. 56, pp. 172-180 (2013). [cited by applicant]
Jakobovits et al., “Production of fully human antibodies by transgenic mice,” Curr. Opin. Biotechnol., vol. 6, Issue 5, pp. 561-566 (1995). [cited by applicant]
Janssens et al., “Generation of heavy-chain-only antibodies in mice,” PNAS, vol. 103, No. 41, pp. 15130-15135 (2006). [cited by applicant]
Jin et al., “Oligoclonal expansion of TCR Vδ T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia,”Journal of Hematology & Oncology vol. 9:126, pp. 1-7 (2016). [cited by applicant]
Kabelitz et al., “The primary response of human gamma/delta+ T cells to Mycobacterium tuberculosis is restricted to Vgamma 9-bearing cells.”, The Journal of experimental medicine 173.6, pp. 1331-1338 (1991). [cited by applicant]
Kabelitz and He, “The Multifunctionality of Human Vγ9Vδ2 γδ T Cells: Clonal Plasticity or Distinct Subsets? : Plasticity of Human γδ T Cells,” Scandinavian Journal of Immunology, vol. 76, pp. 213-222 (2012). [cited by applicant]
Kang et al., “Adoptive immunotherapy of lung cancer with immobilized anti-TCRγδ antibody-expanded human γδ T-cells in peripheral blood,” Cancer Biology & Therapy, vol. 8, Issue 16, pp. 1540-1549 (2009). [cited by applicant]
Kim and Hong, “Humanization by CDR Grafting and Specificity-Determining Residue Grafting,” Methods in Molecular Biology, vol. 907, pp. 237-245 (2012). [cited by applicant]
Klebanoff et al, “CD8+ T-cell memory in tumor immunology and immunotherapy,”Immunol Rev., vol. 211, pp. 214-224 (2006). [cited by applicant]
Kress et al., Distinct gene expression in human Vδ1 and Vδ2 γδ T cells following non-TCR agonist stimulation, Molecular Immunology, vol. 43, pp. 2002-2011 (2006). [cited by applicant]
Kondo et al., “Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy,” Cytotherapy, vol. 10, No. 8, pp. 842-856 (2008). [cited by applicant]
Lamb and Lopez, “γδ T cells: A New Frontier for Immunotherapy?,” Biology of Blood and Marrow Transplantation, vol. 11, pp. 161-168 (2005). [cited by applicant]
Lang et al., “Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma,” Cancer Immunol Immunother, vol. 60, pp. 1447-1460 (2011). [cited by applicant]
LeFranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Developmental & Comparative Immunology, vol. 27, pp. 55-77 (2003). [cited by applicant]
Li et al, “Transgenic mice with a diverse human T cell antigen receptor repertoire,” Nature Med. vol. 16, pp. 1029-1035 (2010). [cited by applicant]
Linguiti et al, “Genomic and expression analyses of T cell receptor gamma (TRG) and alph/delta (TRA/TRD) loci reveal a similar basic public γδ repertoire in dolphin and human,” MBC Genomics, vol. 17, No. 634, pp. 1-17 (… [cited by applicant]
Lloyd et al, “Modelling the human immune response: perfomance of a 10 [cited by applicant]
Lopez et al., “CD2-mediated IL0120dependent signals render human −T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the d… [cited by applicant]
Luoma et al., “γδ T cell surveillance via CD1 molecules,” Trens in Immunolgoy, vol. 35, No. 12, pp. 613-621 (2014). [cited by applicant]
Malmborg et al., “BIAcore as a tool in antibody engineering,” J. Immunol. Methods, vol. 183, pp. 7-13 (1995). [cited by applicant]
Mangan et al., “Cutting Edge: CD1d Restriction and Th1/Th2/Th17 Cytokine Secretion by Human V 3 T Cells,” J. of Immunol., vol. 191, pp. 30-34 (2013). [cited by applicant]
Michie et al., “Lifespan of human lymphocyte subsets defined by CD45 isoforms,” Nature, vol. 360, pp. 364-365 (1992). [cited by applicant]
Moonka and Loh, “A consensus primer to amplify both α and β chains of the human T cell receptor,” Journal of Immunological Methods, vol. 169, pp. 41-51 (1994). [cited by applicant]
Nagamine et al., Induction of γδ T Cells Using Zoledronate Plus Interleukin-2 in Patients with Metastatic Cancer, Hiroshima J. Med. Sci, vol. 58, No. 2, pp. 37-44 (2009). [cited by applicant]
Nakajima et al., “A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous γδ T cells,” European Journal of Cardio-thoracic Surgery, vol. 37, pp. 1191-1197 (2010). [cited by applicant]
Nicol et al., “Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours,” British Journal of Cancer, vol. 105, pp. 778-786 (2011). [cited by applicant]
Nussbaumer et al., “Essential Requirements of Zoledronate-Induced Cytokine and γδ T Cell Proliferative Responses,”, J. of Immunol., vol. 191, No. 3, pp. 1346-1355 (2013). [cited by applicant]
Oberg et al., “γδ T cell activation by bispecific antibodies,” Cellular Immunology, vol. 296, pp. 41-49 (2015). [cited by applicant]
Petros et al., “Improved analysis of TCR γδ variable region expression in humans,” Journal of Immunological Methods, vol. 434, pp. 66-72 (2016). [cited by applicant]
Peyrat et al., “Repertoire analysis of human peripheral blood lymphocytes using a human V delta 3 region-specific monoclonal antibody. Characterization of dual T cell receptor (TCR) delta-chain expressors and alpha beta… [cited by applicant]
Qi et al., “Immobilized MICA Could Expand Human Vδ1 γδT Cells in Vitro that Displayed Major Histocompatibility Complex Class I Chain-Related A-Dependent Cytotoxicity to Human Epithelial Carcinomas.” Scandinavian Journal… [cited by applicant]
Rei et al., “The Emerging Protumor Role of γδ T Lymphocytes: Implications for Cancer Immunotherapy,” Cancer Research, vol. 75(5), pp. 798-802 (2015). [cited by applicant]
Romagne F et al, “Structural analysis of gammadelta TCR using a novel set of TCR gamma and delta chain-specific monoclonal antibodies generated against soluble gammadelta TCR Evidence for a specific conformation adopted… [cited by applicant]
Sagar et al., “In vivo immunogenicity of Tax(11-19) epitope in HLA-A2/DTR transgenic mice: Implication for dendritic cell-based anti-HTLV-1 vaccine,” Vaccine, vol. 32, , pp. 3274-3284 (2014). [cited by applicant]
Saitoh et al., “Anti-tumor cytotoxicity of γδ T cells expanded from peripheral blood cells of patients with myeloma and lymphoma,” Med Oncol., vol. 25, pp. 137-147 (2008). [cited by applicant]
Sallusto et al., “Two subsets of memory T lymphocytes with distinct homing potentials and effector functions,” Nature, vol. 401, p. 708-712 (1999). [cited by applicant]
Scheinberg et al., “Reaching Un-Drugable Intracellular Targets with the Long Arm of Antibodies,” Oncotarget, vol. 4(5), pp. 647-648 (2013). [cited by applicant]
Scheper et al., “Hunting for clinical translation with innate-like immune cells and their receptors”, Leukemia, vol. 28, No. 6, pp. 1181-1190 (2014). [cited by applicant]
Shang et al., “Rational optimization of tumor epitopes using in silico analysis-assisted substitution of TCR contact residues,” European Journal of Immunology, vol. 39, pp. 2248-2258 (2009). [cited by applicant]
Sheriff and Constantine, “Redefining the minimal antigen-binding fragment,” Nature Struct. Biol., vol. 3, No. 9, pp. 733-736 (1996). [cited by applicant]
Siegers et al., “Human V delta 1 gamma delta T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells”, Cytoherapy, vol. 13, No. 6, pp. 753-764 (2011… [cited by applicant]
Siegers et al., “Extensive expansion of primary human gamma delta T cells generates cytotoxic effector memory cells that can be labeled with Feraheme for cellular MRI”, Cancer Immunol. Immunother, vol. 62(3), pp. 571-58… [cited by applicant]
Taupin et al., “An enlarged subpopulation of T lymphocytes bearing two distinct [gamma][delta] TCR in an HIV-positive patient”, International Immunology, vol. 11, No. 4, pp. 545-552 (1999). [cited by applicant]
TermoFisher Cientific—Useful Numbers for Cell Culture—obtained from www.thermofisher.com/US/en/home/references/gibo-cell-culture-basics/cell-culture-protocols/cell-culture-useful-numbers.html on Apr. 5, 2016 via the Way… [cited by applicant]
Vantourout et al., “Specific requirements for Vγ9Vδ2 T cell stimulation by a natural adenylated photphoantigen”, J. Immunol., vol. 183(6), pp. 3848-3857 (2009). [cited by applicant]
Weidanz et al., “TCR-Like Biomolecules Target Peptide/MHC Class I Complexes on the Surface of Infected and Cancerous Cells,” Int. Rev. Immunol., vol. 30, pp. 328-340 (2011). [cited by applicant]
Wild et al., “Dependence of T Cell Antigen Recognition on the Dimensions of an Accessory Receptor-Ligand Complex,” J. Exp. Med, vol. 190, No. 1, pp. 31-41 (1999). [cited by applicant]
Wilhelm et al., “γδ T cells for immune therapy of patients with lymphoid malignancies, ” Blood, vol. 102, No. 1, pp. 200-206 (2003). [cited by applicant]
Wilhelm et al., “Successful adoptive transfer and in vivo expansion of haploidentical γδ T Cells,” J Transl Med., vol. 12, pp. 1-6 (2014). [cited by applicant]
Wistuba-Hamprecht K, Pawelec G, Derhovanessian E. OMIP-020: phenotypic characterization of human γδ T-cells by multicolor flow cytometry. Cytometry A., vol. 85(6) pp. 522-524 (2014). [cited by applicant]
Wu et al., “Ex vivo expanded human circulating Vδ1 γδ T cells exhibit favorable therapeutic potential for colon cancer,” Oncoimmunology, vol. 4:3, pp. e992749-13 (2015). [cited by applicant]
Xu et al., “Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities,” Immunity, vol. 13, pp. 37-45 (2000). [cited by applicant]
Yin, et al., “Hyperactivation and in situ recruitment of inflammatory Vδ2 T cells contributes to disease pathogensissi in systemic lupus erythematosus,”, Scientific Reports 5:14432, pp. 1-12 (2015). [cited by applicant]
Yoon et al., “The Cell Cycle Time of CD8+ T Cells Responding in Vivo is Controlled by the Type of Antigenic Stimulus,” PLOS One, vol. 5(11), pp. 1-12 (2010). [cited by applicant]
Yu et al., “Expansion and Immunological Study of Human Tumor Infiltrating Gamma-Delta T Lymphocytes in vitro,” Int Arch Allergy Immunol, vol. 119, pp. 31-37 (1999). [cited by applicant]
Zapata et al., “Engineering linear F(ab')2 fragments for efficient production in [cited by applicant]
Zhou et al., “Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies,” Cellular & Molecular Immunology, vol. 9, pp. 34-44 (2012). [cited by applicant]